The earnings result
Regeneron Pharmaceuticals reported earnings on 2023-02-03 for the fiscal quarter ending Dec/2022. Reported EPS of $10.96 compared with a consensus estimate of $8.18, a beat on the source's earnings measure.
An EPS comparison describes one part of the release. Revenue, segment performance, cash conversion, guidance and the conference-call discussion require the original company disclosures; the result alone does not establish why the stock moved.
The market response
Price baseline: report-date close; announcement time unavailable. The source does not identify whether this report was before or after trading. These are subsequent daily returns, not a verified immediate earnings reaction.
The first measured session returned -0.29% from the stated baseline. The five-session return was -3.26%, and the 20-session return was -0.35%. SPY returned -1.91% across the corresponding window. Relative volume was 1.51 times the preceding 20-session average.
This edition is a source-based earnings-result and market-response analysis. A full financial-statement and conference-call dossier is not yet attached.